After weeks of planning, the fund-raising walk for Bridger Gustafson will take place this Saturday, June 13, at Constitution Park in Lovell. The fun-for-the-family event will take place at 7 a.m. Bridger, the 5-year-old son of Blake and JanaLee Moncur Gustafson of Carrollton, Texas, and the grandson of Brent and...
Latest News
After five of his seven siblings were diagnosed with Huntington’s disease (HD) in the past seven years, Robert Robinson and his wife, Laura, sprang to action. In an energetic quest, they became involved in the P.E.I. Chapter of Huntington Society of Canada and attended a national conference in Charlottetown last...
Greg Perlman and his giving platform, Change Reaction, were able to raise a total of $13,500 for Harmon Jones and his family. The family of a 4-year-old boy who is recovering from cancer has a generous donor to thank for helping change their lives and get them back on their...
When Lisa Doo planned a yard sale last year to benefit research for Moyamoya disease, of which her son Justin is stricken, most folks in the Walpole area had never heard of the disease. Now, with another sale planned for Saturday, more residents are aware of Justin’s case, but Lisa...
Basel, Switzerland – Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions like schizophrenia or depression. Remembering a code for long enough to type it in; holding a...
TURKU, Finland and BOSTON, Mass. — Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announced that the first patient has been dosed in Phase 2 of the BEXMAB trial that evaluates the...
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM:FARN, First North:FARON), a clinical-stage biopharmaceutical company, today announced updated full data from its Phase 1/2 BEXMAB study, presented at the American Society of Hematology (ASH) 2025 Annual Meeting (oral and poster presentation). The data highlights significant improvement in survival outcome and new findings on...
TURKU, Finland – Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel treatments for medical conditions with significant unmet needs, today announced that two abstracts featuring data from the Phase 1/2 BEXMAB study have been accepted for presentation at the American Society of Hematology (ASH) 2025 Annual Meeting....
Study highlights: Ex vivo treatment of AML and MDS bone marrow samples with bexmarilimab led to increased antigen-presenting human leukocyte antigen DR isotype (HLA-DR) expression, indicating improved antigen presentation capacity. Bexmarilimab , when combined with azacitidine or venetoclax, enhanced HLA-DR expression and in many samples, reduced the viability of leukemic blasts, particularly in...
Houston, Texas – Rice University researchers have developed a rapid, accurate test for diagnosing malaria that is significantly faster and easier to use than traditional tests. The advancement has the potential to improve patient outcomes, especially in rural regions with limited health care resources. Malaria remains a significant global health...